Stockscreener 앱 받기
1.59
2.58%
0.04
시간 외 거래:
1.59
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
Fmr LLC Has $515,000 Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017 - BioSpace
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages - MarketBeat
The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - StockTitan
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Longview News-Journal
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online
Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance
RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Announces Participation at Upcoming Healthc - GuruFocus.com
Regulus Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences - StockTitan
Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat
Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com
Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World
RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com
Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com
What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat
Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat
Regulus: Q3 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Yahoo Finance
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
2.88%
2.65%
자본화:
|
볼륨(24시간):